Hosted on MSN2h
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...
FierceBiotech9h
Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
BioSpace1d
Novo Launches Citizen Petition to Block Compounded Victoza
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...
BioSpace1d
Novo-Backed Oral Medicine Biotech Adds Lilly to Investors in $93M Series A
Orbis emerged from stealth in February 2024 with $28.1 million in seed funding. The Danish biotech, which aims to flip ...
Novo Nordisk seeks to block compounded Victoza
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...